Angina (Angina Pectoris) - Pipeline Review, H1 2020
Angina (Angina Pectoris) - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.
Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 2, 3, 4 and 3 respectively.
Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.
Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 2, 3, 4 and 3 respectively.
Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Ark Therapeutics Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Research Institute
XyloCor Therapeutics Inc
Angina (Angina Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-1018972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ivabradine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Angina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Ark Therapeutics Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Research Institute
XyloCor Therapeutics Inc
Angina (Angina Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-1018972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ivabradine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Angina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Angina (Angina Pectoris), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H1 2020
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Angina (Angina Pectoris) - Discontinued Products, H1 2020
Number of Products under Development for Angina (Angina Pectoris), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H1 2020
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020
Angina (Angina Pectoris) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Angina (Angina Pectoris) - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Angina (Angina Pectoris), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Angionetics Inc
Ark Therapeutics Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Research Institute
XyloCor Therapeutics Inc
Number of Products under Development for Angina (Angina Pectoris), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Angionetics Inc
Ark Therapeutics Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Research Institute
XyloCor Therapeutics Inc
